- Home
- VRAR vs NRXS Comparison
VRAR vs NRXS Comparison
Compare VRAR & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- NRXS
- Stock Information
- Founded
- VRAR 2016
- NRXS 2011
- Country
- VRAR United States
- NRXS United States
- Employees
- VRAR N/A
- NRXS N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- NRXS
- Sector
- VRAR Technology
- NRXS
- Exchange
- VRAR Nasdaq
- NRXS Nasdaq
- Market Cap
- VRAR 29.1M
- NRXS 25.8M
- IPO Year
- VRAR 2021
- NRXS 2023
- Fundamental
- Price
- VRAR $1.63
- NRXS $3.00
- Analyst Decision
- VRAR Strong Buy
- NRXS Strong Buy
- Analyst Count
- VRAR 1
- NRXS 1
- Target Price
- VRAR $2.62
- NRXS $7.00
- AVG Volume (30 Days)
- VRAR 315.5K
- NRXS 55.1K
- Earning Date
- VRAR 11-13-2025
- NRXS 11-11-2025
- Dividend Yield
- VRAR N/A
- NRXS N/A
- EPS Growth
- VRAR N/A
- NRXS N/A
- EPS
- VRAR N/A
- NRXS N/A
- Revenue
- VRAR $10,527,925.00
- NRXS $3,217,531.00
- Revenue This Year
- VRAR $16.26
- NRXS $62.14
- Revenue Next Year
- VRAR $43.33
- NRXS $131.87
- P/E Ratio
- VRAR N/A
- NRXS N/A
- Revenue Growth
- VRAR 19.58
- NRXS 41.93
- 52 Week Low
- VRAR $0.50
- NRXS $1.33
- 52 Week High
- VRAR $7.00
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- VRAR 51.91
- NRXS 60.01
- Support Level
- VRAR $1.40
- NRXS $2.98
- Resistance Level
- VRAR $1.78
- NRXS $3.24
- Average True Range (ATR)
- VRAR 0.17
- NRXS 0.17
- MACD
- VRAR -0.00
- NRXS 0.03
- Stochastic Oscillator
- VRAR 48.83
- NRXS 67.50
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).